Publication
Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.
Francesca Maines, Ugo De Giorgi, Gaetano Facchini, Lucia Fratino, Donatello Gasparro, Daniele Alesini, Umberto Basso, Marcello Tucci, Cinzia Ortega, Sarah Scagliarini, Francesco Verderame, Sandro Barni, Alessandro D'Angelo, Giovanni Vicario, Maddalena Donini, Francesco Carrozza, Teodoro Sava, Zuzana Sirotova, Daniele Santini, Orazio Caffo
Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2016.34.2_suppl.210